Close

BioPharma

Key Steps For Biopharma Startups Getting Ready For EU HTA

What is the Joint European HTA? Navigating pricing and reimbursement in the European Union (EU) can be a complex task for emerging biopharmaceutical companies (EBPs), defined as those with less than $200 million in estimated annual R&D spending or global...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development and manufacturing organization (CDMO) is pivotal to a successful pharmaceutical development journey. This decision hinges on two critical factors: a customer-centric approach and team cohesion. In this blog, we explore...

Overcoming Challenges In Biopharma Novel Drug Manufacturing

The biopharmaceutical sector is undergoing a significant transformation in treating complex diseases, especially in oncology, driven by innovative drug approaches. This shift entails personalized therapies, combination treatments, and novel go-to-market strategies to address specific patient groups. As the industry...

Enhanced Biopharmaceutical Release: Autonomous PAT Power

Speeding up biomanufacturing using automated Process Analytical Technology (PAT) systems A2P2 and Micro Sequential Injection (SI), two cutting-edge process analysers, have been cited as autonomous PAT platform that enables quick testing and release of biopharmaceutical products. An insight has showcased two...

Overcoming Treatment Challenges With Cell And Gene Therapies

Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with traditional medicine. These therapies involve introducing, replacing, or deactivating genes in cells, either inside or...

Boosting Innovation And Value In UK Biopharma And Medtech

New recommendations from Imperial College London aim to boost competitiveness in the UK's biopharma and Medtech sectors. It assesses the value-added per capita in these sectors and provides insights into their needs, challenges, and opportunities. Technological solutions and policy...

Cell And Gene Therapy CDMO Services Market Is On The Rise

The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is expected to grow at a CAGR of 17.5% during the forecast period from 2023 to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read